Mayo Test Dooms Breakthrough Biotech Invention
The Federal Circuit recently handed down a long-awaited Section 101 decision, one with potentially far-reaching consequences for biotech diagnostic patents. In Ariosa Diagnostics Inc. v. Sequenom Inc., No. 14-1139 (Fed. Cir. June...To view the full article, register now.
Already a subscriber? Click here to view full article